Drug therapies in dermatology

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 14, Issue 1, 2014, Pages 47-53

  Aslam, Arif ^a   Griffiths, Christopher E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Atopic dermatitis; Biological therapies; Malignant melanoma; Psoriasis; Tumour necrosis factor antagonists

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; APREMILAST; BARICITINIB; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; BRODALUMAB; CYCLOSPORIN A; DABRAFENIB; DACARBAZINE; DAPSONE; DERMATOLOGICAL AGENT; EMOLLIENT AGENT; ETANERCEPT; FILAGGRIN; INFLIXIMAB; INGENOL MEBUTATE; IPILIMUMAB; IXEKIZUMAB; METHOTREXATE; OMALIZUMAB; PROPRANOLOL; PSORALEN; SECUKINUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB; VEMURAFENIB; VISMODEGIB;

ADVANCED CANCER; ATOPIC DERMATITIS; BIOLOGICAL THERAPY; CAPILLARY HEMANGIOMA; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC URTICARIA; CLINICAL PRACTICE; DERMATOLOGY LIFE QUALITY INDEX; DRUG EFFICACY; DRUG TOLERABILITY; FAMILY HISTORY; HEADACHE; HELPER CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INJECTION SITE REACTION; KERATINOCYTE; METASTATIC MELANOMA; MOLECULAR WEIGHT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; SKIN DEFECT; SKIN DISEASE; SKIN INFECTION; SUPPURATIVE HIDRADENITIS; SYSTEMIC THERAPY; T LYMPHOCYTE; TRANSLATIONAL RESEARCH; UPPER RESPIRATORY TRACT INFECTION;

ATOPIC DERMATITIS; BIOLOGICAL THERAPIES; MALIGNANT MELANOMA; PSORIASIS; TUMOUR NECROSIS FACTOR ANTAGONISTS;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DERMATITIS, ATOPIC; HUMANS; MELANOMA; PSORIASIS; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896738634     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.14-1-47     Document Type: Review

References (47)

1. Griffiths CEM, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71.
2. Nestle FO, Kaplan DH, Barker JN. Psoriasis. N Engl J Med 2009;361:496-509.
3. Gottlieb AB. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 2005;4:19-34.
4. Lowes MA, Kicuchi T, Fuentes-Duclucan J et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 cells. J Invest Dermatol 2008;128:1207-11.
5. Mrowietz U, Elder JT, Barker JN. The importance of disease associations and concomitant therapy for the long term management of psoriasis patients. Arch Dermatol Res 2006;298:309-19.
6. National Institute for Health and Care Excellence. Psoriasis. The assessment and management of psoriasis (NICE clinical guideline 153). London: NICE, 2012.
7. Yamauchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy and safety. Dermatol Clin 2004;22:440-59.
8. Krueger CG, Elewski B, Papp K et al. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomised placebo controlled trial. J Am Acad Dermatol 2006;56:598-603.
9. Papp KA, Tyring S, Lahfa M et al. A global phase III randomised controlled trial of etanercept in psoriasis: safety, efficacy and effect on dose reduction. Br J Dermatol 2005;152:1304-12.
10. Menter A, Tyring S, Gordon A et al. Adalimumab therapy for moderate to severe psoriasis: a randomised controlled phase III trial. J Am Acad Dermatol 2008;58:106-15.
11. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate to severe psoriasis: a phase III multicentre double blind trial. Lancet 2005;366:1367-74.
12. Cargill M, Schrodi SJ, Chang M et al. A large scale association study confirms IL-12B and leads to identification of IL-23R as psoriasis risk genes. Am J Hum Genet 2007;80:273-90.
13. Robertson MJ, Ritz J. Interleukin 12: basic biology and potential applications for cancer treatment. Oncologist 1996;1:88-97.
14. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody in patients with psoriasis: 76 week results from a randomised double blind placebo controlled trial (PHOENIX I). Lancet 2008;371:1665-74.
15. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody in patients with psoriasis: 52 week results from a randomised double blind, placebo controlled trial (PHOENIX II). Lancet 2008;371:1675-84.
16. Nograles KE, Zaba LC, Guttman-Yassky E et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte response pathways. Br J Dermatol 2008;159:1092-102.
17. Kryczek I, Bruce AT, Gudjonsson JE et al. Induction of IL-17 T cell trafficking and development by IFN- : mechanism and pathological relevance in psoriasis. J Immunol 2008;181:4733-41.
18. Rich P, Sigurgeirsson B, Thaci D et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised double blind, placebo controlled, phase II regimen finding study. Br J Dermatol 2012;168:402-11.
19. Papp KA, Langley RG, Sigurgeirsson B et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomised double blind, placebo controlled phase II dose ranging study. Br J Dermatol 2012;168:412-21.
20. Leonardi C, Matheson R, Zachariae C et al. Anti-interleukin-17 monoclonal antibody Ixekinumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9.
21. Russell C, Kerkof K, Bigler J et al. Blockade of the IL-17R with AMG 827 leads to a rapid reversal of gene expression and histopathologic abnormalities in human psoriatic skin. J Invest Dermatol 2010;130:S46.
22. Papp KA, Leonardi C, Menter A et al. Brodalumab an interleukin-17 receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9.
23. Meyer DM, Jesson MI, Li X et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550 in rat adjuvant induced arthritis. J Inflamm 2010;7:41.
24. Papp KA, Menter A, Strober B et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor in the treatment of psoriasis: a phase 2b randomised placebo controlled dose-ranging study. Br J Dermatol 2012;167:668-77.
25. van Vollenhoven RF. Small molecular compounds in development for rheumatoid arthritis. Curr Opin Rheumatol 2013;25:391-7.
26. Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Design Dev Ther 2013;7:201-10.
27. Papp KA, Kaufmann R, Thaci D et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicentre, randomised double blind placebo controlled parallel group dose comparison study. J Eur Acad Dermatol Venereol 2012; doi: 10.1111/j.1468-3083. 2012.04716.x.
28. Papp KA, Cather JC, Rosoph L et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012;380:738-46.
29. US National Library of Medicine, 2013. http://ClinicalTrials.gov [Accessed 3 December 2013].
30. Goldsmith D, Kuhlmann M, Covic A. Through the looking glass: the protein science of biosimilars. Clin Exp Nephrol 2007;11:191-5.
31. Fleischmann R, Shealy D. Developing a new generation of TNF-α antagonists for the treatment of rheumatoid arthritis. Mol Inter 2003;3:310-8.
32. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003;112:S118-27.
33. Brown SJ, McLean WHI. One remarkable molecule: Filaggrin. J Invest Dermatol 2012;132:751-62.
34. Saini S, Rosen K, Hsieh HJ et al. A randomised placebo controlled dose ranging study of single dose omalizumab in patients with H1 antihistamine refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128:567-73.
35. Cancer Research UK. CancerStats key facts. Skin cancer. London: Cancer Research UK, 2013.
36. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
37. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.
38. Chapman PB, Hauschild A, Robert C et al. BRIM-3 study group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
39. Chapman PB, Hauschild A, Robert C. Updated overall survival (OS) results for BRIM-3, a phase III randomised open label multicentre trial comparing BRAF inhibitor vemurafenib with dacarbazine in previously untreated patients with BRAF V600E mutated melanoma. J Clin Oncol 2012;30: Abstract 8502.
40. Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207-15.
41. Kirkwood JM, BREAK-MB: a phase II study assessing overall intracranial pressure to dabrafenib in patients with BRAF V600E/K mutation positive melanoma with brain metastases. J Clin Oncol 2012;301: Abstract 8501.
42. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
43. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
44. Aszterbaum M, Rothman A, Johnson RL et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell naevus syndrome. J Invest Dermatol 1998;110:885-8.
45. Stockfleth E, Ferrandiz C, Grob JJ et al. Development of a treatment algorithm for actinic keratoses:a European Consensus. Eur J Dermatol 2008;18:651-9.
46. Lebwohl M, Swanson N, Anderson L et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012;366:1010-9.
47. Lèautè-Labréze C, Dumas de la Roque E, Hubiche T et al. Propranolol for severe haemangiomas of infancy. N Engl J Med 2008;358:2649-51.